PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDsLaurie Herviou(Centre National de la Recherche Scientifique), Jérôme Moreaux(Hôpital Saint Eloi)Clinical EpigeneticsOctober 3, 201810.1186/s13148-018-0554-4Cited by 47SaveCiteExport RISWatch citationsRelated PapersAntioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells|Cancers|2019|30Identification of a 20-Gene Expression-Based Risk Score as a Predictor of Clinical Outcome in Chronic Lymphocytic Leukemia Patients|BioMed Research International|2014|20